Could a diabetes drug help schizophrenia patients lose weight?
NCT ID NCT05333003
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether semaglutide, a drug used for diabetes and weight loss, can help people with schizophrenia who are overweight or obese and did not lose weight on metformin. About 92 participants will receive either semaglutide or a placebo. The main goal is to see if semaglutide leads to significant weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide
- What this could lead to
- If it works, this could offer a new weight-loss option for people with schizophrenia who haven't had success with metformin.
- What could go wrong
- This is a small, early-stage trial with no phase designation. The results may not apply to everyone, and semaglutide can cause side effects like nausea or vomiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
Toronto, Ontario, M6J 1H4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a web app get people moving in mental health residential care?
- Smartwatch data may forecast bipolar mood swings
- Could a talking therapy ease the weight of bipolar depression?
- Blood inflammation may hold clues to psychiatric diagnosis
- Could a common antibiotic and supplement lift bipolar depression?
- Brain markers may reveal who responds best to suicide treatments